During the first quarter of 2026, Bio-Works reported net sales of 29.3 MSEK, a significant increase from the previous year's 9.0 MSEK, primarily due to large deliveries in Europe. The operating profit improved to 4.1 MSEK from a loss of 7.8 MSEK in the same quarter of the previous year, and the profit for the quarter was 4.7 MSEK compared to a loss of 8.0 MSEK last year. The cash flow was positive at 6.3 MSEK, and cash and cash equivalents grew to 41.3 MSEK by the end of March. However, the order intake decreased to 15.5 MSEK from 31.6 MSEK. Personnel costs increased due to new hires and more working hours, while other external costs rose mainly because of higher sales. Earnings per share improved to +0.05 SEK before dilution and +0.04 SEK after dilution. CEO Lone Carlbom highlighted the company's strong start to 2026, emphasizing positive operating profit and a solid financial position. The company is focusing on building global presence, increasing large customer numbers, and maintaining cost discipline to achieve sustainable profitable growth. Bio-Works aims to strengthen its role in the biopharmaceutical production chain, contributing to recurring business. The company is headquartered in Uppsala, Sweden, and operates globally, supplying products through direct sales and distributors. Bio-Works is listed on the Spotlight Stock Market.

Under första kvartalet 2026 ökade Bio-Works nettoomsättning till 29,3 MSEK jämfört med 9,0 MSEK samma period föregående år, främst tack vare stora leveranser i Europa. Rörelseresultatet förbättrades till 4,1 MSEK från -7,8 MSEK, och kvartalsresultatet blev 4,7 MSEK jämfört med -8,0 MSEK året innan. Kassaflödet var positivt med 6,3 MSEK jämfört med -4,4 MSEK föregående år. Orderingången minskade till 15,5 MSEK från 31,6 MSEK. Personalkostnaderna ökade till 9,0 MSEK på grund av nyanställningar, medan övriga externa kostnader steg till 8,5 MSEK. Resultat per aktie ökade både före och efter utspädning. Likvida medel vid kvartalets slut var 41,3 MSEK. VD Lone Carlbom rapporterar en stark start på 2026 med positivt rörelseresultat och vinst, samt ett stärkt kassaflöde. Företaget upplever en positiv utveckling i kundrelationer och affärsvolymer. Bio-Works fokuserar på att stärka sin globala närvaro och öka antalet stora kunder, samtidigt som de upprätthåller kostnadsdisciplin. Målet är att uppnå långsiktig lönsam tillväxt. Bio-Works är verksamt inom bioteknikbranschen och levererar lösningar för rening av biomolekyler globalt. Huvudkontoret ligger i Uppsala, Sverige, och företaget är noterat på Spotlight Stock Market.

Bio-Works Technologies AB has received an order worth approximately 4.2 million SEK for 230 liters of WorkBeads 40S from a returning European customer involved in peptide contract manufacturing. This order underscores the company's strong reputation in the chromatography products market and supports its sales targets for the year, with delivery scheduled for the third quarter of 2026. Bio-Works is based in Uppsala, Sweden, and provides global bioprocessing solutions, certified under ISO 9001:2015, and is listed on the Spotlight Stock Market.

Bio-Works Technologies AB har mottagit en order värd cirka 4,2 miljoner SEK för 230 liter WorkBeads 40S från en återkommande europeisk kund inom kontraktstillverkning av peptider. Ordern, som ska levereras under tredje kvartalet 2026, stärker företagets försäljningsmål och bekräftar kundernas förtroende för deras produkter. Bio-Works är baserat i Uppsala, Sverige, och erbjuder lösningar för bioteknikbranschen globalt. Företaget är certifierat enligt ISO 9001:2015 och noterat på Spotlight Stock Market. Informationen offentliggjordes den 29 april 2026.

On April 16, 2026, Bio-Works Technologies AB concluded the sixth exercise period for its TO 2 warrants, initially issued during a rights issue in August 2024. A total of 586,229 warrants were exercised, resulting in the same number of new shares being subscribed, generating SEK 586,229 for the company before costs. The conversion of interim shares to ordinary shares is expected around April 28, 2026. This exercise increases the company's total shares to 100,010,822 and the share capital to SEK 10,001,082.2, with an approximate dilution of 0.59% for shareholders who did not exercise their warrants. There are still 16,928,548 TO 2 warrants available for trading on the Spotlight Stock Market. The next exercise opportunity for these warrants is from July 1 to July 14, 2026. The financial advisor for this process is Sedermera Corporate Finance, with Foyen Advokatfirma as the legal advisor and Nordic Issuing AB as the issuing agent. Bio-Works, headquartered in Uppsala, Sweden, specializes in biomolecule purification solutions for the biotechnology industry and is listed on the Spotlight Stock Market. The press release includes legal disclaimers about securities trading and forward-looking statements, emphasizing that it does not constitute an offer to trade securities outside of Sweden, and highlights the applicability of the Act on the Screening of Foreign Direct Investments, requiring certain investors to notify authorities if their shareholding surpasses specific thresholds.

Den 16 april 2026 avslutades den sjätte nyttjandeperioden för Bio-Works Technologies AB:s teckningsoptioner av serie TO 2, vilka emitterades i samband med en företrädesemission 2024. Totalt 586 229 optioner nyttjades för att teckna lika många nya aktier, vilket tillförde bolaget 586 229 SEK före emissionskostnader. Detta ökade antalet aktier i bolaget till 100 010 822 och aktiekapitalet till 10 001 082,2 SEK, med en utspädningseffekt på cirka 0,59 procent för aktieägare som inte nyttjade optionerna. Nästa nyttjandeperiod för TO 2 är planerad till 1–14 juli 2026. Bio-Works är noterat på Spotlight Stock Market och har sitt huvudkontor i Uppsala, Sverige.

År 2025 var ett genombrottsår för Bio-Works, med betydande tillväxt och förbättrade finansiella resultat. Det fjärde kvartalet var särskilt starkt, vilket bekräftar företagets affärsmodell. Omsättningen ökade kraftigt, med rekordhög orderingång och en stabil orderbok inför 2026. Rörelseresultatet närmade sig ett positivt resultat, och företaget fokuserade på kommersialisering och produktlanseringar. Bio-Works har stärkt sin finansiella ställning och ökat produktionskapaciteten. Företaget har även etablerat ett strategiskt partnerskap i Sydkorea som en del av sin globala expansion. Bio-Works, baserat i Uppsala, levererar lösningar för bioprocessing globalt och är noterat på Spotlight Stock Market.

Eva Lindskog and Andrea Ballagi have been proposed as new board members for Bio-Works. Lindskog, born in 1973, has over 15 years of experience in senior roles within the Life Science industry, focusing on bioprocessing and analytical technologies. She is currently the Chief Commercial Officer at NanoTemper Technologies and has held senior positions at Sartorius, Lonza, and GE Healthcare Life Sciences. She holds a Master of Science in Chemical Engineering and a PhD in Bioprocess Technology from KTH Royal Institute of Technology. Andrea Ballagi, born in 1965, brings nearly 30 years of experience in the Life Science sector, focusing on biotech product commercialization and international business development. She is currently the Global Head of Market Development in Oncology at Olink Proteomics AB. Ballagi has held senior roles at Olink and IDEXX Laboratories, including being CEO of a Swedish subsidiary. She is a physician with a PhD from the Ludwig Institute of Cancer Research and an MBA from Uppsala University. Peter Ehrenheim, Chairman of Bio-Works, welcomes their nomination, highlighting their expertise in bioprocessing and scaling Life Science companies. The Nomination Committee for the 2026 Annual General Meeting includes Elisabet Tunon, Erik Åfors, and Jonas Ahlén, with a full opinion to be published later. Bio-Works, based in Uppsala, Sweden, supports biotech companies in biomolecule purification and is listed on Spotlight Stock Market.

Today marks the start of the sixth exercise period for Bio-Works Technologies AB's TO 2 warrants, which were issued as part of a rights issue in August 2024. Holders of these warrants can subscribe for new shares at SEK 1 each during one of eleven designated exercise periods. The current period runs from April 1 to April 16, 2026. Initially, 38,979,790 TO 2 warrants were issued, with 21,465,013 already exercised, leaving 17,514,777 outstanding. Full exercise of these remaining warrants would increase the company's shares by the same amount, resulting in a 15% dilution of capital and votes. Bio-Works, based in Uppsala, Sweden, provides bioprocessing solutions globally and is listed on the Spotlight Stock Market. The company advises investors to refer to the prospectus published before the exercise period for comprehensive information. The press release also includes contact details for further inquiries and mentions the applicability of the Act on the Screening of Foreign Direct Investments, requiring notification for certain investment thresholds.

Bio-Works Technologies AB har inlett den sjätte nyttjandeperioden för sina teckningsoptioner av serie TO 2, som emitterades under en företrädesemission i augusti 2024. Innehavare av dessa optioner kan nu teckna nya aktier i bolaget för 1 SEK per aktie mellan 1 april och 16 april 2026. Totalt finns det 38 979 790 teckningsoptioner av serie TO 2, och hittills har 21 465 013 av dessa nyttjats. Vid fullt nyttjande av de återstående optionerna skulle antalet aktier i Bio-Works öka med 17 514 777, vilket motsvarar en utspädning på cirka 15%. Informationen om detta erbjudande finns på Bio-Works hemsida. Sedermera Corporate Finance AB, Foyen Advokatfirma och Nordic Issuing AB är rådgivare i processen. Bio-Works är ett företag inom bioteknik med huvudkontor i Uppsala och är noterat på Spotlight Stock Market. Pressmeddelandet innehåller även en varning om att det inte utgör ett erbjudande att förvärva värdepapper och att investerare bör basera sina beslut på det officiella prospektet. Det finns också information om lagkrav för utländska direktinvesteringar.

Bio-Works Technologies AB reported preliminary net sales of 29.3 MSEK for the first quarter of 2026, with comparisons of 9.0 MSEK. Net sales for the last two quarters were 53.0 MSEK compared to 11.6 MSEK, and for the last four quarters, 82.8 MSEK compared to 28.5 MSEK. The order intake for the first quarter of 2026 was 15.5 MSEK, with a comparison of 31.6 MSEK, and the order book as of March 31, 2026, stood at 17.7 MSEK. These figures are part of a new reporting strategy to provide faster information to investors. Bio-Works, headquartered in Uppsala, Sweden, supports biotech companies in biomolecule purification and is listed on the Spotlight Stock Market. For further details, contact Arne Hauge, CFO, or visit their website.

Bio-Works is focusing on strengthening its position in the growing biological applications market, including the purification of peptides, oligonucleotides, and monoclonal antibodies. Their products are involved in numerous global drug development projects and commercial manufacturing programs. The company sees significant commercial opportunities in Europe, North America, and Asia, with China as a key market. They project potential revenues of SEK 250–500 million over the next 3–5 years. CEO Lone Carlbom reported improvements in commercial development, growth across applications, and operational efficiency. The global biopharmaceutical market is expected to grow significantly, with the chromatography resin market also expanding rapidly. Bio-Works increased its production capacity by 80% in 2025 and is considering further expansion. Financially, the company improved its gross margin to 77% and is fully financed until break-even, expected by 2027. Bio-Works aims to continue supporting customers in bioprocessing, with headquarters in Uppsala, Sweden, and a global product supply network. The company is listed on the Spotlight Stock Market.